Plasma Protein Therapeutics Market by Product (Albumins, C1-esterase Inhibitors, Coagulation Factors), Application (Hereditary Angioedema, Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiency Disorder) - Global Forecast 2024-2030

[183 Pages Report] The Plasma Protein Therapeutics Market size was estimated at USD 32.55 billion in 2023 and expected to reach USD 36.19 billion in 2024, at a CAGR 11.37% to reach USD 69.18 billion by 2030.

Plasma protein therapeutics consist of medications derived from human plasma, the liquid component of the blood that contains essential proteins responsible for various functions necessary to human health. These therapeutics include an array of highly specialized treatments tailored to address a variety of medical conditions resulting from the absence or malfunctioning of specific plasma proteins. The market for plasma protein therapeutics includes developing, producing, and distributing these proteins for clinical use. Increased prevalence of autoimmune and neurological diseases, along with the increasing need for regular infusions or injections throughout the life of the patient, contribute to the growth of the plasma protein therapeutics market. Surging access and affordability of plasma protein therapies for patients also fuel the market development. The adverse effects of plasma protein therapeutics and strict regulations about handling plasma protein are restricting market growth. Increasing research and development activity related to the plasma protein presents a potential opportunity for growth in the plasma protein therapeutics market. The development of an efficient protein plasma extraction/manufacturing process is expected to create growth in the market.

The plasma protein therapeutics market in the Americas is highly developing, with the United States being one of the major global markets, driven by advanced healthcare infrastructure, high patient awareness levels, and the presence of key industry players. The regulatory environment fostered by the FDA ensures stringent quality and safety standards. In South America, Brazil and Argentina are emerging as key markets for plasma protein therapeutics due to growing healthcare expenditures and awareness about plasma-derived therapies. The Asia-Pacific (APAC) region presents a growth opportunity for the plasma protein therapeutics market, attributed to rising healthcare awareness, increasing disposable incomes, and a growing aging population. China and Japan are significant markets in this region, with China investing heavily in plasma collection and fractionation capabilities. Europe has well-established healthcare systems, high-quality standards, and favorable reimbursement policies. The need for immunoglobulins remains robust, and European countries are significant exporters of plasma products. The Gulf Cooperation Council (GCC) countries demonstrate a rising need for plasma protein therapeutics due to economic prosperity and increased healthcare spending. Conversely, Africa faces considerable hurdles in healthcare infrastructure and treatment access, although the interest in plasma-derived medicinal products is growing.

The market dynamics represent an ever-changing landscape of the Plasma Protein Therapeutics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

• Market Drivers
  • Increased Prevalence of Autoimmune and Neurological Diseases
  • Need for Regular Infusions or Injections Throughout the Life of the Patient
  • Surging Access and Affordability of Plasma Protein Therapies for Patients
• Market Restraints
  • Adverse Effects of Plasma Protein Therapeutics
• Market Opportunities
  • Increasing Research and Development Activity Related to the Plasma Protein
  • Development of Efficient Protein Plasma Extraction/Manufacturing Process
• Market Challenges
  • Strict Regulations Pertaining to Handling of Plasma Protein

• Product: Rising usage of C1-esterase inhibitors to control and prevent the swelling attacks associated with HAE

  Albumin, a protein synthesized by the liver, is responsible for maintaining oncotic blood pressure and transporting hormones, enzymes, and drugs. In therapeutics, albumins are often used as volume expanders in cases of shock or burns and to treat hypoalbuminemia due to liver failure, nephrotic syndrome, or gastrointestinal protein loss. C1-esterase inhibitors are proteins that regulate the complement system, which is part of the body's immune response. They are primarily used to treat hereditary angioedema (HAE), a rare genetic condition that causes swelling in various parts of the body. Coagulation factors are essential proteins in the blood clotting process. Therapeutic coagulation factors prevent and control bleeding in individuals with hemophilia A and B, which are genetic disorders that impair blood clotting. Treatments involve replacing defective or missing clotting factors, which can be administered prophylactically to prevent bleeding episodes or on-demand to manage acute bleeding. Hyperimmune globulins are plasma-derived immunoglobulins with high concentrations of antibodies targeting specific pathogens or toxins. They are used to prevent or treat diseases such as hepatitis B, rabies, tetanus, and certain types of infections in immunocompromised patients. Immunoglobulins (Ig), also known as antibodies, are used in treating a wide array of autoimmune and inflammatory diseases, primary and secondary immunodeficiencies, and certain infections. Intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) are the two main forms offered, with the choice largely depending on patient preference, tolerability, and vein accessibility. Specific clinical needs lead to the choice among plasma protein products. Albumins and coagulation factors provide critical volume and clotting functions, respectively, often with high-urgency use cases like trauma and surgery and bleeding control for the latter. C1-esterase inhibitors and hyperimmune globulins offer more targeted interventions, focusing on genetic and infectious diseases. Immunoglobulins have the broadest application range, treating various autoimmune and immunodeficiency-related conditions. The manufacturing landscape is dominated by a few key players who robustly respond to medical needs, emphasized by recent advancements such as gene therapies and expanded indications for existing treatments.

• Application: Growing application of plasma protein therapeutics in the secondary immunodeficiency due to prevalence of cancer and autoimmune diseases

  Hereditary angioedema is a rare genetic disorder indicated by sudden, severe, and unpredictable swelling in various parts of the body. Treatment for HAE involves C1 esterase inhibitor (C1-INH) concentrates and, more recently, recombinant C1-INH therapies and kallikrein inhibitors as on-demand treatment and prevention. The need for these therapies is high, given the life-threatening nature of HAE attacks. Idiopathic thrombocytopenic purpura is an autoimmune disease that results in a low platelet count, leading to easy bruising and bleeding. Intravenous immunoglobulin (IVIG) is generally used to treat ITP, as it can quickly elevate platelet counts. Primary Immunodeficiency Disorders (PID) represent a group of over 300 disorders where part of the body's immune system is missing or functions improperly. Patients typically require lifelong therapy, often with immunoglobulin (Ig) replacement. Secondary Immunodeficiency (SID) arises when an external source such as infection, chemotherapy, or another disease impairs the immune system. The therapeutic needs across these four application segments vary significantly, with demand being shaped by both the acuteness and the chronic nature of each condition. While HAE and ITP typically require rapid response treatments, PID and SID require longer-term management strategies.

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Plasma Protein Therapeutics Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

The value chain of the Plasma Protein Therapeutics Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of thePlasma Protein Therapeutics Market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

The regulatory framework analysis for the Plasma Protein Therapeutics Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Plasma Protein Therapeutics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Plasma Protein Therapeutics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

• GC Biopharma's groundbreaking for the plasma fractionation plant in Indonesia

  GC Biopharma Corp inaugurated a plasma fractionation facility at the Jababeka Industrial Estate in Indonesia. This initiative builds on GC Biopharma's distinguished global plasma product plant construction record, with successful deployments in Thailand, China, and Canada. [Published On: December 05, 2023]

• PlasmaGen Biosciences Opens New, State-of-the-Art Manufacturing Facility for Blood Plasma Products in Kolar, Bengaluru

  PlasmaGen Biosciences inaugurated its advanced blood plasma-derived therapeutics manufacturing plant in Kolar, Bengaluru. The facility, which spans 8 acres, incorporates sophisticated independent but interlinked blocks designed for efficient operational workflows. [Published On: May 30, 2023]

• Takeda to build USD 770 million plasma-derived therapy plant in Japan

  Takeda Pharmaceutical Company Limited announced a significant investment in the Japanese healthcare infrastructure by constructing a state-of-the-art USD 770 million facility in Osaka. This venture, which is Takeda's most substantial manufacturing capacity expansion in Japan, is set to be the plasma protein therapeutic (PDT) plant in the country. [Published On: March 27, 2023]

The report delves into recent significant developments in the Plasma Protein Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Bio Products Laboratory Ltd., CSL Limited, Takeda Pharmaceutical Company Limited, DiaPharma, GC Biopharma corp, AmerisourceBergen Corporation, Laboratory Corporation of America Holdings, Bruker Corporation, Octapharma AG, KalVista Pharmaceuticals, Emergent BioSolutions, FFF Enterprises, Inc., Plasma Technologies, LLC, LFB SA, Kamada Ltd., PlasmaGen BioSciences Pvt. Ltd., Reliance Industries Limited, Thermo Fisher Scientific, Inc., Grifols, S.A., China Biologic Products Holdings, Inc., Hemarus Therapeutics Limited, Access Biologicals LLC, ADMA Biologics, Inc., Baxter International Inc., and Kedrion S.p.A..

This research report categorizes the Plasma Protein Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Albumins
  • C1-esterase Inhibitors
  • Coagulation Factors
  • Hyperimmune Globulins
  • Immunoglobulins
• Application
  • Hereditary Angioedema
  • Idiopathic Thrombocytopenic Purpura
  • Primary Immunodeficiency Disorder
  • Secondary Immunodeficiency

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

1. What is the current market size and projected growth?
2. Which products, segments, applications, and regions offer promising investment opportunities?
3. What are the prevailing technology trends and regulatory frameworks?
4. What is the market share and positioning of the leading vendors?
5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?